Pharma’s Digital Pathology Build-Out; Part 1

Pharma’s Digital Pathology Build-Out; Part 1 – The State Of Play

21 Nov 2022

• By Rachel Laing, Sophie Peltre, and Mark Ratner

Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?

Build out — Pharma is building digital pathology capacity • Source: Shutterstock

Large pharmaceutical companies are eager to talk about their digital transformation and their whole-hearted adoption of computational biology and artificial intelligence (AI). In the same vein, many are enthusiastically emphasizing the contributions digital pathology is making throughout their R&D organizations.

Digital pathology is helping pharma across the spectrum of drug discovery and development. (See Exhibit 1.) The technology digitizes hematoxylin...